Evogene Ltd. (EVGN) Stock

About Evogene Ltd.

Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components. The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybean, wheat, rice, and cotton. The Industrial Applications segment focuses on enhancing castor bean seeds for use as a raw material in various industrial applications. Meanwhile, the Human Health segment is dedicated to uncovering and developing human microbiome-based treatments for conditions including immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. Beyond these core areas, Evogene also delivers medical cannabis products. The company maintains a global presence, conducting operations in the United States, Israel, Brazil, and other international markets. It has forged key partnerships and licensing agreements with leading agricultural enterprises, such as BASF SE, Corteva, and Bayer. Additionally, its subsidiary, Canonic Ltd., collaborates with Cannbit Ltd. on the development of innovative medical cannabis offerings. Established in 1999, Evogene Ltd. is based in Rehovot, Israel.

Evogene Ltd. is led by CEO Ofer Haviv, employs 117 people, headquartered in IL, publicly traded since 2010.

Evogene Ltd. (EVGN) stock trades at $0.54 with a market capitalization of $4.67M. The stock is valued at a price-to-earnings (P/E) ratio of -0.41, price-to-book of -2.18, price-to-sales of 2.66. Over the past 52 weeks the stock has ranged between $0.37 and $1.50, and currently trades 64.0% below its 52-week high.

On profitability, Evogene Ltd. generates a return on equity (ROE) of 937.72% — well above the market average, a sign of a high-quality business, return on capital employed of -111.38%, an operating margin of -350.00%, a net profit margin of -639.39%.

Official website: www.evogene.com